Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors – Fierce Biotech
- Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors Fierce Biotech
- One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible. The New York Times
- A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia investor.lilly.com
- Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study statnews.com
- New data bolster Lilly’s bet on Verve-developed PCSK9 editor FirstWord Pharma
المصدر: Google News — UK / BUSINESS
0
مشاهدة
